CURRENT METHODS TO REALIZE THE REPRODUCTIVE FUNCTION IN PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME AND CHRONIC ENDOMETRITIS

L. M. Malanchuk, A. S. Khmil Doswald

I Horbachevsky Ternopil National Medical University of MOH of Ukraine
e-mail: klinika_khmil@ukr.net

Abstract

Literature review indicates that both polycystic ovary syndrome (PCOS) and chronic endometritis (CE) have a significant role in implantation disorders, one of the main causes of infertility and unsuccessful outcomes of assisted reproductive technologies.

Study aim was to analyze the literature on current methods to recover reproductive function in patients with polycystic ovarian syndrome and chronic endometritis.

Materials and methods. The review analyzed scientific literature published in the past decade, as well as relevant research publications available in the online databases, which were searched using the key words "polycystic ovary syndrome", "endometritis", "comorbidity", and "infertility".

Results. While the evidence of positive effects of lifestyle changes on fertility is inconclusive, weight loss is a first-line treatment option recommended for women with PCOS. International guidelines for women with anovulatory PCOS consistently recommend as a second-line option gonadotropin therapy to induce ovulation if oral first-line induction ovulatory therapy, including aromatase inhibitors and selective estrogen receptor modulators,
fails. In regards to the treatment of CE, research supports the use of antibiotic therapy which increases the incidence of pregnancy in women with CE and repeated unsuccessful implantation, infertility of unknown ethiology or recurrent miscarriage.

**Conclusions.** Current methods of restoring reproductive function in patients with PCOS and chronic endometritis include a wide range of non-pharmacological and pharmacological treatments of PCOS in combination with antibiotic therapy of chronic endometritis, but their effectiveness remains low, which requires the use of assisted reproductive technologies.

**Key words:** polycystic ovary syndrome; chronic endometritis; comorbidity; infertility; treatment.

**Introduction**

Infertility affects 40% of women with polycystic ovary syndrome (PCOS) [1]. Among the risk factors for infertility against the background of PCOS are overweight, which is diagnosed in 90% of patients, and is an independent factor that reduces the effectiveness of infertility treatment and causes a higher risk of miscarriage [2]. Another factor that is closely correlated with infertility is age. Psychological and emotional state is also a notable factor in reducing female fertility [3]. Thus, an open discussion of fertility problems is considered to be playing an important role in the treatment of infertility comorbid with PCOS [4, 5].

At the same time, studies have shown that the incidence of chronic endometritis (CE) in infertile patients ranges from 0.2 to 46% [6]. In several studies, CE diagnosis ranged from 2.8 to 67.6% of patients with infertility and implantation failure [7–13]. It is generally understood that CE, even if not clinically manifested, reduces the effectiveness of both natural and assisted reproductive technologies, in addition to being a contributing factor in the development of obstetric and neonatal complications [14].

In summary, literature review indicates that both PCOS and CE play a substantial role in the failure of implantation processes as one of the main causes of infertility and unsuccessful rounds of assisted reproductive technologies.

**Study aim** was to analyze the literature on current methods of reproductive function in patients with PCOS and chronic endometritis.
Materials and methods
The review examined research publications from the last decade, including highly cited papers indexed in online databases, which were selected after a search with keywords "polycystic ovary syndrome", "endometritis", "comorbidity", and "infertility".

Results and discussion
While the evidence for lifestyle changes to restore fertility remains inconclusive, weight loss is recommended as a first-line treatment option for women with PCOS [15]. A healthy diet and regular physical activity help to reduce insulin resistance and hyperandrogenism, as well as balance hormonal and lipid profiles [16, 17]. Some studies suggest that weight loss in infertile women with both overweight and PCOS is be associated with sporadic ovulation and a better response to ovulation-stimulating treatment, as well as with an increase in pregnancy and live birth rates [18, 19]. For instance, a decrease in body weight of only 5% from baseline can restore regular menstruation and improve the response to drugs for ovulation and fertility [20]. In addition, sustained physical activity can improve fertility results by modulating the hypothalamic-pituitary-gonadal axis[21].

Since 70% of women with PCOS are diagnosed with anovulation or oligoovulation, ovulation induction is essential for the treatment of infertility in women with PCOS.

Clomiphene citrate is a selective estrogen receptor modulator (SERM), which traditionally was considered the first treatment of choice for ovulation induction in women with PCOS. Current guidelines suggest the use of clomiphene citrate as a second-line therapy to improve ovulation and pregnancy in women with PCOS with anovulatory infertility and no other infertility factors (conditional recommendation) [15]. It acts as an antiestrogen by blocking estrogen receptors in the hypothalamus, leading to an increase in the release of the gonadotropin-releasing hormone (GnRH) and, subsequently, increased production of the anterior pituitary follicle-stimulating hormone (FSH) and luteinizing hormone (LH), stimulating complete follicle maturation. The antiestrogenic action can also affect the endometrium and cervical mucus, inhibiting endometrial proliferation, which could potentially inhibit implantation [22]. Tamoxifen acts similarly to clomiphene citrate and is used to treat anovulation in patients who do not respond to clomiphene citrate. Due to the effect of tamoxifen on the uterine mucosa, studies of combined clomiphene and tamoxifen administration have shown a marked increase in pregnancy [23].

Letrozole is an inhibitor of aromatase, the enzyme converting androgen to estrogen, and it is the most commonly used selective third-generation nonsteroidal inhibitor for ovulation induction [24]. Letrozole inhibits the secretion of estradiol by the ovaries. This
results in increased both the secretion of FSH by the pituitary gland and the sensitivity of follicles to FSH, with subsequent improvement in ovulation rate [25]. Since letrozole, compared to clomiphene citrate, has a relatively short half-life (approximately 45 hours), there is no adverse effect on estrogen target tissues [26].

International guidelines maintain the recommendation to use gonadotropin therapy for ovulation induction in women with anovulatory PCOS as a second-line option for those patients who do not respond to first-line oral induction ovulation therapy, including aromatase inhibitors and selective estrogen receptor modulators [15].

In patients with PCOS, gonadotropins are associated with an increased risk of ovarian hyperstimulation syndrome (OHSS) and multiple pregnancies. Exogenous FSH stimulates the proliferation of granulosa cells and follicle growth. Different gonadotropin preparations are equally effective, without significant variability in the frequency of live births, clinical frequency of pregnancy, frequency of multiple pregnancies, frequency of miscarriages or incidence of OHSS [27, 28].

In combination gonadotropin therapy with metformin, Bordewijk et al. found a higher cumulative level of live births compared to FSH alone, while there was insufficient data on the incidence of multiple pregnancies and other adverse events [29]. Similarly, Palomba et al. demonstrated that the introduction of metformin significantly increases the number of live births and the frequency of pregnancies, while at the same time reducing the frequency of miscarriages [30].

Metformin is a biguanide insulin sensitizer, commonly used as the first-line antihyperglycemic agent to treat Type 2 diabetes. In the ovaries, metformin reduces androgen production by the theca cells by reducing the activity of ovarian cytochrome P450c17a and the expression of steroidogenic acute regulatory protein [31, 32]. Ovarian hyperandrogenism is responsible for premature follicular atresia and anovulation, so metformin may in theory stimulate ovulation [33].

A meta-analysis by Panda et al. showed that orlistat, an anti-obesity drug that reduces the absorption of fat in the gut, is more effective than metformin in reducing body weight, LDL cholesterol, total cholesterol and insulin resistance [34]. Another meta-analysis to evaluate the efficacy and safety of glucagon-like peptide-1 (GLP1) receptor agonists showed that GLP1 receptor agonists were also more effective than metformin in improving insulin sensitivity and reducing BMI, suggesting that these medications may be a good choice for obese PCOS patients, especially those with insulin resistance [35].
Given the development of insulin resistance in patients with PCOS, inositol (hexahydroxycyclohexane) may be an effective treatment option, with two stereoisomeric forms of myoinositol (MI) and D-chiroinositol (DCI) each playing a corresponding biological role as insulin sensitizing agents [22, 36]. In the ovaries, MI mediates glucose uptake and FSH signaling, while DCI improves insulin-induced androgen synthesis [22, 37]. Depletion of MI and overabundance of DCI in the ovaries due to increased epimerase activity can impair the quality of oocytes [38]. Pundir et al. found a significant improvement in ovulation rate and normalization of menstrual cycles with the use of inositol [39]. In addition, MI supplementation was shown to restore spontaneous ovulation with subsequent increase in conception rates, both alone and in combination with gonadotropins [40]. Currently, international guidelines suggest considering inositol as an experimental therapy for PCOS.

Given the crucial role of insulin resistance and oxidative stress in the pathological mechanisms of PCOS, the combination of inositol and alpha-lipoic acid is a promising therapeutic approach without significant adverse effects on women with PCOS [41]. Alpha-lipoic acid is a powerful scavenger of free radicals and a natural cofactor of mitochondrial dehydrogenase complexes. Research findings show that alpha-lipoic acid activates 5’ adenosine monophosphate-activated protein kinase (AMPK), which lowers triacylglycerol levels and improves endothelial function [42]. When used alone or in combination with inositol, alpha-lipoic acid improves glucose control, insulin resistance, and ameliorates metabolic and endocrine disorders in patients with PCOS [43-45]. Both inositol and alpha-lipoic acid can improve metabolism and endocrine parameters by acting as both insulin sensitizers and antioxidants [46–48].

Currently under study is the effectiveness of a combined preparation Sinopol, which is a new three-in-one formula containing alpha-lipoic acid (400 mg), myoinositol (1000 mg) and folic acid (200 mcg). This combination of ingredients is designed to decrease endocrine and metabolic imbalances associated with insulin resistance and reproductive health in women with PCOS [49–52]. Since there are no identifiable side effects of any of these components when used for therapeutic purposes, in recent years research focus has shifted to identify new natural compounds and combinations as alternative treatments of PCOS, in particular, the combinations of inositol with monacolins or bergamot flavonoids [53 - 56].

Worth mentioning among the plethora of various vitamin preparations is vitamin D. The deficiency of this vitamin in women of reproductive age ranges from 45 to 90% [57, 58]. One study found that vitamin D deficiency in women with PCOS who underwent ovarian stimulation for infertility treatment was associated with a significant reduction in ovulation,
pregnancy, and, ultimately, reduced likelihood of live births [59]. PCOS and vitamin D deficiency are also associated with insulin resistance [60].

Treatment of CE involves antibiotic therapy, which, in a number of studies, improved the incidence of pregnancy in women with CE and a history of repeated unsuccessful implantation [61-63], unexplained infertility [64] or recurrent miscarriage [65]. In addition, patients with CE who underwent antibiotic therapy showed improved incidence of live births, pregnancy and implantation compared to the patients with recurrent CE [63]; and in antibiotic treated CE patients the IVF outcomes were comparable to those of women without CE [63]. In women with repeated unsuccessful implantation, polyvalent treatment of inflamed endometrium often leads to a doubled implantation frequency and the number of live births in assisted reproductive technology programs [66]. In addition, in cases of recurrent miscarriage, there was an increase in the frequency of live births (7 to 56% after treatment) and the cumulative incidence of live births [65]. A study by Lewis et al. where CE was found in 40.7% of women, showed that treatment of CE significantly improved the rate of implantation in patients who underwent in vitro fertilization and embryo transfer [67].

Conclusions. Current approaches to restore reproductive function in patients with PCOS and chronic endometritis include a wide range of non-pharmacological and pharmacological treatment of PCOS in combination with antibiotic therapy for chronic endometritis, but their effectiveness remains low, which requires the use of assisted reproductive technologies.

References
1. Okoroh EM, Hooper WC, Atrash HK, Yusuf HR, Boulet SL. Prevalence of polycystic ovary syndrome among privately insured, United States 2003–2008, Obstet. Gynecol. 2012; (4): 299. American.
2. Brassard, M., AinMelk, Y. and Baillargeon, JP. Basic Infertility Including Polycystic Ovary Syndrome. The Medical Clinics of North America. 2008; (92): 1163-1192. American.
3. A review: Brief insight into Polycystic Ovarian syndrome. Jeshica Bulsara, Priyanshi Patel, Arun Soni, Sanjeev Acharya. Endocrine and Metabolic Science. 30 June 2021.Vol. 3: 100085. USA.
4. RV Bharathi, S. Swetha, J. Neerajaa, JV Madhavica, DM Janani, SN Rekha, S. Ramya, B. Usha. An epidemiological survey: Effect of predisposing factors for PCOS in Indian urban and rural population. Middle East Fertility Society Journal, 2017; (4): 313-316.
5. Kauffman RP, Baker VM, Dimarino P., Gimpel T., Castracane VD. Polycystic ovarian syndrome and insulin resistance in white and Mexican American women: A comparison of two distinct populations. Am. J. Obstet. Gynecol. 2002; 187: 1362–1369.

6. Carvalho FM, Aguiar FN, Tomioka R, de Oliveira RM, Frantz N, et al. Functional endometrial polyps in infertile asymptomatic patients: a possible evolution of vascular changes secondary to endometritis. Eur J Obstet Gynecol Reprod Biol 2013; (170): 152-156.

7. Smith M, Hagerty KA, Skipper B, Bocklage T. Chronic endometritis: a combined histopathological and clinical review of cases from 2002 to 2007. Int J Gynecol Pathol. 2010; 29 (1): 44–50.

8. Johnston-MacAnanny EB, Hartnett J, Engmann LL, Nulsen JC, Sanders MM, Benadiva CA. Chronic endometritis is a frequent finding in women with recurrent implantation failure after in vitro fertilization. Fertil Steril. 2010; 93 (2): 437–441.

9. Bouet PE, El Hachem H, Monceau E, Gariepy G, Kadoch JJ, Sylvestre C. Chronic endometritis in women with recurrent pregnancy loss and recurrent implantation failure: prevalence and role of office hysteroscopy and immunohistochemistry in diagnosis. Fertil Steril. 2016; 105 (1): 106–10.

10. Cicinelli E, Matteo M, Trojano G, Mitola PC, Tinelli R, Vitagliano A, et al. Chronic endometritis in patients with unexplained infertility: prevalence and effects of antibiotic treatment on spontaneous conception. Am J Reprod Immunol. 2018; 79 (1): 12782.

11. Liu Y, Chen X, Huang J, Wang CC, Yu MY, Laird S, et al. Comparison of the prevalence of chronic endometritis as determined by means of different diagnostic methods in women with and without reproductive failure. Fertil Steril. 2018; 109 (5): 832–9.

12. Song D, Feng X, Zhang Q, Xia E, Xiao Y, Xie W, et al. Prevalence and confounders of chronic endometritis in premenopausal women with abnormal bleeding or reproductive failure. Reprod Biomed Online. 2018; 36 (1): 78–83.

13. Tersoglio AE, Salatino DR, Reinchisi G, Gonzalez A, Tersoglio S, Marlia C. Repeated implantation failure in oocyte donation. What to do to improve the endometrial receptivity? JBRA Assist Reprod. 2015; 19 (2): 44–52.

14. Moreno I, Cicinelli E, Garcia-Grau I, et al. The diagnosis of chronic endometritis in infertile asymptomatic women: a comparative study of histology, microbial cultures, hysteroscopy, and molecular microbiology. Am J Obstet Gynecol; 218: 602. 1-16

15. Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018; 110: 364–379.
16. Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2011; (2): 110 - 112. France.

17. Pasquali R, Casimirri F, Vicennati V. Weight control and its beneficial effect on fertility in women with obesity and polycystic ovary syndrome. Hum Reprod. 1997; (12): 82–87.

18. Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 1992; 36: 105–111.

19. Legro RS, Dodson WC, Kunselman AR, et al. Benefit of delayed fertility therapy with preconception weight loss over immediate therapy in obese women with PCOS. J Clin Endocrinol Metab. 2016; 101: 2658–2666.

20. Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril. 2009; 92: 1966–1982.

21. Hakimi O, Cameron LC. Effect of exercise on ovulation: a systematic review. Sports Med. 2017;47:1555–1567.

22. Homburg R. Clomiphene citrate—end of an era? A mini-review. Hum Reprod. 2005; 20; 2043–2051.

23. Close LK Dhaliwal, V. Suri, KR Gupta, S. Sahdev. Tamoxifen: An alternative to clomiphene in women with polycystic ovary syndrome. J.Hum.Reprod.Sci., 2020; 4 (2): 76

24. Tanbo T, Mellembakken J, Bjercke S, Ring E, Abyholm T, Fedorcsak P. Ovulation induction in polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2018; 97: 1162–7.

25. Casper RF. Aromatase inhibitors in ovarian stimulation. J Steroid Biochem Mol Biol. 2007; 106: 71–75.

26. Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril. 2001;75:305–309.

27. Weiss NS, Kostova E, Nahuis M, Mol BWJ, van der Veen F, van Wely M.Gonadotrophins for ovulation induction in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019;1:CD010290.

28. Ikenaga H, Tanaka Y, Shiotani M, et al. Phase III trial comparing the efficacy and safety of recombinant- or urine-derived human chorionic gonadotropin for ovulation triggering in Japanese women diagnosed with anovulation or oligo-ovulation and undergoing ovulation induction with follitropin-alfa. Reprod Med Biol. 2017;16:45–51.
29. Bordewijk EM, Nahuis M, Costello MF, et al. Metformin during ovulation induction with gonadotrophins followed by timed intercourse or intrauterine insemination for subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev. 2017; 1: 165 – 170.

30. Palomba S, Falbo A, La Sala GB. Metformin and gonadotropins for ovulation induction in patients with polycystic ovary syndrome: a systematic review with meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2014; 12: 3.

31. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med. 1996; 335: 617–623.

32. Attia GR, Rainey WE, Carr BR. Metformin directly inhibits androgen production in human thecal cells. Fertil Steril. 2001; 76: 517–524.

33. Utiger RD. Insulin and the polycystic ovary syndrome. N Engl J Med. 1996; 335: 657–658.

34. Panda SR, Jain M, Jain S, Saxena R, Hota S. Effect of orlistat versus metformin in various aspects of polycystic ovarian syndrome: a systematic review of randomized control trials. J Obstet Gynaecol India 2018; 68: 336–343.

35. Han Y, Li Y, He B. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. Reprod Biomed Online. 2019; 39: 332–42.

36. Showell MG, Mackenzie-Proctor R, Jordan V, Hodgson R, Farquhar C. Inositol for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2018; 12: 128 -134.

37. Monastra G, Unfer V, Harrath AH, Bizzarri M. Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients. Gynecol Endocrinol. 2017; 33: 1–9.

38. Facchinetti F, Bizzarri M, Benvena S, et al. Results from the international consensus conference on myo-inositol and D-chiro-inositol in obstetrics and gynecology: the link between metabolic syndrome and PCOS. Eur J Obstet Gynecol Reprod Biol. 2015; 195: 72–76.

39. Pundir J, Sunkara SK, El-Toukhy T, Khalaf Y. Meta-analysis of GnRH antagonist protocols: do they reduce the risk of OHSS in PCOS. Reprod Biomed Online. 2012; 24: 6–22.

40. Cappelli V, Musacchio MC, Bulfoni A, Morgante G, De Leo V. Natural molecules for the therapy of hyperandrogenism and metabolic disorders in PCOS. Eur Rev Med Pharmacol Sci. 2017; 21(2): 15-29.
41. El Hayek S, Bitar L, Hamdar LH, et al. Polycystic ovarian syndrome: an updated overview. Front Physiol 2016; (7) :124.

42. Masharani U, Gjerde C, Evans JL, Youngren JF, Goldfine ID. Effects of controlled-release alpha lipoic acid in lean, nondiabetic patients with polycystic ovary syndrome. J Diabetes Sci Technol. 2010 ; 4(2): 359 - 364.

43. Di Tucci C, Di Felicianonio M, Vena F, et al. Alpha lipoic acid in obstetrics and gynecology. Gynecol Endocrinol 2018; 34: 729–33.

44. Genazzani AD, Shefer K, Della Casa D, et al. Modulatory effects of alpha-lipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients. J Endocrinol Invest 2018; 41: 583–590.

45. Fruzzetti F, Capozzi A, Canu A, et al. Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome. Gynecol Endocrinol 2019; 35: 506–510.

46. Unfer V, Porcaro G. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome. Expert Rev Clin Pharmacol 2014; 7: 623–31.

47. Nestler JE, Unfer V. Reflections on inositol(s) for PCOS therapy: steps toward success. Gynecol Endocrinol 2015; 31: 501–505.

48. Thomas MP, Mills SJ, Potter BV. The other” inositols and their phosphates: synthesis, biology, and medicine (with recent advances in myo-inositol chemistry). Angew Chem Int Ed Engl 2016; 55: 1614–1615.

49. Rago R, Marcucci I, Leto G, et al. Effect of myo-inositol and alpha-lipoic acid on oocyte quality in polycystic ovary syndrome non-obese women undergoing in vitro fertilization: a pilot study. J Biol Regulators Homeostatic Agents 2015; 29(4): 1-11.

50. Genazzani AD, Shefer K, Della Casa D, et al. Modulatory effects of alphalipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients. J Endocrinol Invest 2018; 41: 583–590.

51. Carbonelli MG, Di Renzo L, Bigioni M, et al. α-Lipoic Acid Supplementation: A Tool for Obesity Therapy. Curr Pharmaceut Design 2010; 16: 840-846.

52. De Cicco S, Immediata V, Romualdi D, et al. Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action. Gynecol Endocrinol 2017; 33(9): 698–701.

53. De Leo V, Tosti C, Cappelli V, Morgante G, Cianci A. Valutazione dell’associazione inositolo-glucomannano nel trattamento di donne affette da PCOS. Minerva Ginecol 2014; 66: 527-533.
54. Mollace V, Sacco I, Janda E, Malara C, Ventrice D, Colica C, Visalli V, Muscoli S, Ragusa S, Muscoli C, Rotiroti D, Romeo F. Hypolipemic and hypoglycaemic activity of bergamot poyphenols: from animal models to human studies. Fitoterapia 2011; 82: 309-331.

55. Cappello AR, Dolce V, Iacopetta D, Martello M, Fiorillo M, Curcio R, Muto L, Dhanyalayam D. Bergamot (Citrus bergamia Risso) flavonoids and their potential benefits in human hyperlipidemia and atherosclerosis: an overview. Mini Rev Med Chem 2016; 16: 619-629.

56. Tosti C, Cappelli V, De Leo V. Role of a new oral formulation based on D-chiro-inositol / monacolin K / bergamot extract / methylfolate and Vitamin K2 in perimenopausal women with metabolic syndrome with a BMI >25 kg / m2. J Metab Syndrome 2016; 5: 3 - 4.

57. Bodnar LM, Simhan HN, Powers RW, Frank MP, Cooperstein E, Roberts JM. High prevalence of vitamin D insufficiency in black and white pregnant women residing in the northern United States and their neonates. J Nutr. 2007; 137: 447–452.

58. Nesby-O’Dell S, Scanlon KS, Cogswell ME, et al. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988–1994. Am J Clin Nutr.2002;76:187–192.

59. Butts SF, Seifer DB, Koelper N, et al. Vitamin D deficiency is associated with poor ovarian stimulation outcome in PCOS but not unexplained infertility. J Clin Endocrinol Metab. 2019; 104: 369–378.

60. Lips P, Eekhoff M, van Schoor N, et al. Vitamin D and type 2 diabetes. J Steroid Biochem Mol Biol. 2017; 173: 280–285.

61. Cicinelli E., Matteo M., Tinelli R., Lepera A., Alfonso R., Indraccolo U. Prevalence of chronic endometritis in repeated unexplained implantation failure and the IVF success rate after antibiotic therapy. Hum. Reprod. 2015; 30: 323-330;

62. Kitaya K., Matsubayashi H., Takaya Y., Nishiyama R., Yamaguchi K., Takeuchi T., Ishikawa T. Live birth rate following oral antibiotic treatment for chronic endometritis in infertile women with repeated implantation failure. Am. J. Reprod. Immunol. 2017; 78: 127-129;

63. Vitagliano A., Saccardi C., Noventa M., Di Spiezio A., Saccone G., Cicinelli E., Pizzi S., Andrisani A., Litta PS Effects of chronic endometritis therapy on invitro fertilization outcome in women with repeated implantation failure: a systematic review and meta-analysis. Fertil. Steril. 2018; 110: 103 - 105.
64. Cicinelli E., Matteo M., Trojano G., Mitola PC, Tinelli R., Vitagliano A., Crupano FM, Lepera A., Miragliotta G., Resta L. Chronic endometritis in patients with unexplained infertility: Prevalence and effects of antibiotic treatment on spontaneous conception. Am. J. Reprod. Immunol. 2018; 79: 127-182:

65. McQueen DB, Bernardi LA, Stephenson MD Chronic endometritis in women with recurrent early pregnancy loss and/or fetal demise. Fertil. Steril. 2014; 101: 1026-1030

66. Tersoglio AE, Salatino DR, Reinchisi G., Gonzalez A., Tersoglio S., Marlia C. Repeated implantation failure in oocyte donation. What to do to improve the endometrial receptivity?. JBRA Assist. Reprod. 2015; 19: 44-52:

67. Lewis EI, Brower M, Shamonki M (2013) Treatment of chronic endometritis in women with implantation failure improves implantation in subsequent embryo transfers. Fertil Steril 100: 390.